NEKTAR THERAPEUTICS

NKTR

Exchange NCM, Currency in USD

Loading price...

Overview

Previous Close69.36

Open73.38

Ask81.74

Bid61.06

Day's Range69.60 - 73.68

52 Week Range21.02 - 109.00

PE Ratio(TTM)--

Market Cap2.39B

Volume835.97k

Avg. Volume1.03M

12 Months Earnings-158.10M

12 Months Revenue55.63M

Profit/Loss

PARTICULARS	TTM	2025	2024	2023	2022
Operating Revenue	55.63M	55.23M	98.43M	90.12M	92.06M
Cost of Revenue	0.00	30.69M	33.77M	21.64M
Gross Profit	55.23M	67.74M	56.35M	70.42M
Operating Expenses	180.30M	186.00M	197.66M	191.58M	310.66M
Profit after Tax (Net Income)	-158.10M	-164.08M	-118.96M	-276.06M	-368.20M

Company Profile

Sector: Healthcare

Industry: Biotechnology

HQ Location: San Francisco, United States

Website: https://www.nektar.com

CEO, President & Director: Mr. Howard W. Robin

Employees: 63

About Company:

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.